CD274 and neoplasm: Tumor-intrinsic factors that contribute to primary and acquired resistance to PD-L1/PD-1 immunotherapy conform a genetic and signaling landscape that prevents immune cell infiltration in the tumor microenvironment (TME) (Figure 3).